Literature DB >> 14694138

Incorporation of pol into human immunodeficiency virus type 1 Gag virus-like particles occurs independently of the upstream Gag domain in Gag-pol.

Shan Cen1, Meijuan Niu, Jenan Saadatmand, Fei Guo, Yue Huang, Gary J Nabel, Lawrence Kleiman.   

Abstract

By using particle-associated reverse transcriptase (RT) activity as an assay for Pol incorporation into human immunodeficiency virus type 1 (HIV-1) Gag virus-like particles (VLPs), it has been found that truncated, protease-negative, Gag-Pol missing cis Gag sequences is still incorporated into Gag VLPs, albeit at significantly reduced levels (10 to 20% of the level of wild-type Gag-Pol). In this work, we have directly measured the incorporation of truncated Gag-Pol species into Gag VLPs and have found that truncated Gag-Pol that is missing all sequences upstream of RT is still incorporated into Gag VLPs at levels approximating 70% of that achieved by wild-type Gag-Pol. Neither protease nor integrase regions in Pol are required for its incorporation, implying an interaction between Gag and RT sequences in the Pol protein. While the incorporation of Gag-Pol into Gag VLPs is reduced 12-fold by the replacement of the nucleocapsid within Gag with a leucine zipper motif, this mutation does not affect Pol incorporation. However, the deletion of p6 in Gag reduces Pol incorporation into Gag VLPs four- to fivefold. Pol shows the same ability as Gag-Pol to selectively package tRNA(Lys) into Gag VLPs, and primer tRNA(3)(Lys) is found annealed to the viral genomic RNA. These data suggest that after the initial separation of Gag from Pol during cleavage of Gag-Pol by viral protease, the Pol species still retains the capacity to bind to both Gag and tRNA(3)(Lys), which may be required for Pol and tRNA(3)(Lys) to be retained in the assembling virion until budding is completed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694138      PMCID: PMC368740          DOI: 10.1128/jvi.78.2.1042-1049.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab.

Authors:  C Berthet-Colominas; S Monaco; A Novelli; G Sibaï; F Mallet; S Cusack
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

2.  Roles of matrix, p2, and N-terminal myristoylation in human immunodeficiency virus type 1 Gag assembly.

Authors:  Y Morikawa; D J Hockley; M V Nermut; I M Jones
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.

Authors:  M A Accola; B Strack; H G Göttlinger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles.

Authors:  I Gross; H Hohenberg; C Huckhagel; H G Kräusslich
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins.

Authors:  M Dettenhofer; X F Yu
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein.

Authors:  M T Burniston; A Cimarelli; J Colgan; S P Curtis; J Luban
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

7.  Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly.

Authors:  X F Yu; L Dawson; C J Tian; C Flexner; M Dettenhofer
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.

Authors:  J T Qiu; R Song; M Dettenhofer; C Tian; T August; B K Felber; G N Pavlakis; X F Yu
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  Cross-linking localization of a HIV-1 reverse transcriptase peptide involved in the binding of primer tRNALys3.

Authors:  E Dufour; J Reinbolt; M Castroviejo; B Ehresmann; S Litvak; L Tarrago-Litvak; M L Andreola
Journal:  J Mol Biol       Date:  1999-01-29       Impact factor: 5.469

10.  The I domain is required for efficient plasma membrane binding of human immunodeficiency virus type 1 Pr55Gag.

Authors:  S Sandefur; V Varthakavi; P Spearman
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more
  16 in total

Review 1.  Aminoacyl-tRNA synthetase complexes: molecular multitasking revealed.

Authors:  Corinne D Hausmann; Michael Ibba
Journal:  FEMS Microbiol Rev       Date:  2008-06-03       Impact factor: 16.408

2.  RNA and Nucleocapsid Are Dispensable for Mature HIV-1 Capsid Assembly.

Authors:  Simone Mattei; Annica Flemming; Maria Anders-Össwein; Hans-Georg Kräusslich; John A G Briggs; Barbara Müller
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

3.  Sequential deletion of the integrase (Gag-Pol) carboxyl terminus reveals distinct phenotypic classes of defective HIV-1.

Authors:  Kevin D Mohammed; Michael B Topper; Mark A Muesing
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

4.  Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production.

Authors:  Wenwen Zheng; Limian Ling; Zhaolong Li; Hong Wang; Yajuan Rui; Wenying Gao; Shaohua Wang; Xing Su; Wei Wei; Xiao-Fang Yu
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

5.  The SIVmac239 Pr55Gag isoform, SIV p43, suppresses proteolytic cleavage of Pr55Gag.

Authors:  Michael G Nicholson; Sheila A Barber; Janice E Clements
Journal:  Virology       Date:  2006-11-07       Impact factor: 3.616

6.  A single amino acid substitution in HIV-1 reverse transcriptase significantly reduces virion release.

Authors:  Chien-Cheng Chiang; Shiu-Mei Wang; Yen-Yu Pan; Kuo-Jung Huang; Chin-Tien Wang
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  Inability of human immunodeficiency virus type 1 produced in murine cells to selectively incorporate primer formula.

Authors:  Min Wei; Yiliang Yang; Meijuan Niu; Laurie Desfosse; Robert Kennedy; Karin Musier-Forsyth; Lawrence Kleiman
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 8.  Formation of the tRNALys packaging complex in HIV-1.

Authors:  Lawrence Kleiman; Christopher P Jones; Karin Musier-Forsyth
Journal:  FEBS Lett       Date:  2010-01-21       Impact factor: 4.124

9.  Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles.

Authors:  Wei-Hao Liao; Kuo-Jung Huang; Yu-Fen Chang; Shiu-Mei Wang; Ying-Tzu Tseng; Chien-Cheng Chiang; Jaang-Jiun Wang; Chin-Tien Wang
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

10.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.